

Sarah Calhoun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5008945/publications.pdf>

Version: 2024-02-01

6
papers

45
citations

1937685

4
h-index

1872680

6
g-index

8
all docs

8
docs citations

8
times ranked

11
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15. <i>Cancer Biology and Therapy</i> , 2022, 23, 65-75.	3.4	6
2	Prolyl Carboxypeptidase Maintains Receptor Tyrosine Kinase Signaling and Is a Potential Therapeutic Target in Triple Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 739.	3.7	1
3	RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC. <i>Scientific Reports</i> , 2022, 12, 1049.	3.3	8
4	Acetyl-CoA synthetases ACSS1 and ACSS2 are 4-hydroxytamoxifen responsive factors that promote survival in tamoxifen treated and estrogen deprived cells. <i>Translational Oncology</i> , 2022, 19, 101386.	3.7	11
5	Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells. <i>Journal of Molecular Cell Biology</i> , 2021, 13, 433-444.	3.3	14
6	Prolyl endopeptidase inhibitor Y-29794 blocks the IRS1-AKT-mTORC1 pathway and inhibits survival and <i>in vivo</i> tumor growth of triple-negative breast cancer. <i>Cancer Biology and Therapy</i> , 2020, 21, 1033-1040.	3.4	5